Echo Therapeutics to Present Clinical Study Results of Its Symphony Transdermal Continuous Glucose Monitoring System at Annual Diabetes Technology Meeting
The Symphony(TM) tCGM System measures the continuous flow of glucosethrough the skin, which is made permeable with Echo's Prelude(TM) SkinPrepSystem, a leading-edge skin permeation device. Information about the meetingcan be found on the Diabetes Technology Society website at:http://www.diabetestechnology.org/index.html
"We are excited to present these positive clinical trial results in apeer-reviewed setting as we continue to build awareness of our Symphony tCGMSystem. These clinical results represent substantial progress in our Symphonydevelopment program," stated Patrick T. Mooney, M.D., Echo's Chairman and CEO."The frequent reference blood measurements in this study with a YSI laboratoryanalyzer enabled us to evaluate Symphony's performance with a high level ofconfidence. We believe Symphony's safety and accuracy data from this study arecomparable to all FDA-approved invasive (needle-based) CGM devices. We lookforward to continued progress in our late-stage Symphony developmentprograms."
About Echo Therapeutics
Echo Therapeutics is focused on transdermal medical devices and specialtypharmaceuticals. Echo is developing the Symphony tCGM System as anon-invasive, wireless, transdermal continuous glucose monitoring (tCGM)system for people with diabetes and for use in hospital critical care units,together with a wide range of novel transdermal reformulations of FDA-approvedproducts.
Forward Looking Statements
Echo's Symphony tCGM System has not yet been approved for sale. Theregulatory approval process for the Symphony tCGM System involves, among otherthings, successfully completing clinical trials and obtaining a premarketapproval, or PMA, from the FDA and corresponding foreign regulatoryauthorities. The PMA process requires Echo to prove the safety and efficacy ofthe Symphony tCGM System to the FDA's satisfaction. This process can beexpensive and uncertain, and there is no guarantee that Echo will be able tosubmit a PMA for the Symphony tCGM System or that such system will be approvedby the FDA in any specific timeframe, or at all. In addition, clinical testingof Echo's products and eventual commercialization of its products are subjectto all of the risks and uncertainties set forth in its periodic reports filedwith the U.S. Securities and Exchange Commission.(C) 2002 - 2008 Echo Therapeutics, Inc. All rights reserved worldwide. Investor Relations Contacts: Patrick T. Mooney, M.D. Chairman & CEO Echo Therapeutics 508-530-0329
SOURCE Echo Therapeutics
You May Also Like